These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12360979)

  • 1. Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions.
    Dazzi F; Szydlo RM; Apperley JF; Goldman JM
    Blood; 2002 Oct; 100(7):2673-4. PubMed ID: 12360979
    [No Abstract]   [Full Text] [Related]  

  • 2. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Tabayashi T; Yamada K; Takeuchi M
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia.
    Ruiz-Argüelles GJ; Gómez-Almaguer D; López-Martínez B; Cantú-Rodríguez OG; Jaime-Pérez JC; González-Llano O
    Haematologica; 2002 Aug; 87(8):894-6. PubMed ID: 12161373
    [No Abstract]   [Full Text] [Related]  

  • 5. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia.
    Champlin R
    Exp Hematol; 1995 Oct; 23(11):1148-51. PubMed ID: 7556522
    [No Abstract]   [Full Text] [Related]  

  • 6. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splenectomy status of the patient may have impact on response to donor lymphocyte infusions.
    Uckan-Cetinkaya D; Unal S; Cetin M; Sarikabadayi U; Aktaş D; Koç Y
    Leukemia; 2007 Sep; 21(9):2049-50; author reply 2050-1. PubMed ID: 17554372
    [No Abstract]   [Full Text] [Related]  

  • 8. Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions.
    Ruiz-Genao DP; F-Peñas P; Daudén E; García-F-Villalta MJ; Fraga J; García-Diez A
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):632-4. PubMed ID: 16684312
    [No Abstract]   [Full Text] [Related]  

  • 9. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
    Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
    Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
    Espérou H; Boiron JM; Cayuela JM; Blanchet O; Kuentz M; Jouet JP; Milpied N; Cahn JY; Faucher C; Bourhis JH; Michallet M; Tanguy ML; Vernant JP; Gabert J; Bordigoni P; Ifrah N; Baruchel A; Dombret H;
    Bone Marrow Transplant; 2003 May; 31(10):909-18. PubMed ID: 12748668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results.
    Miyamura K; Barrett AJ; Kodera Y; Saito H
    Bone Marrow Transplant; 1994 Aug; 14(2):201-9. PubMed ID: 7994233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Reduced-intensity hematopoietic stem cell transplantation and donor lymphocyte infusions for chronic myeloid leukemia].
    Ichinohe T; Ishikawa T
    Nihon Rinsho; 2003 Sep; 61(9):1573-8. PubMed ID: 14515726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation.
    Soiffer RJ; Alyea EP; Ritz J
    J Clin Apher; 1995; 10(3):139-43. PubMed ID: 8582896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.
    Bornhäuser M; Thiede C; Platzbecker U; Kiani A; Oelschlaegel U; Babatz J; Lehmann D; Hölig K; Radke J; Tuve S; Wermke M; Wehner R; Jähnisch H; Bachmann MP; Rieber EP; Schetelig J; Ehninger G; Schmitz M
    Blood; 2011 Jun; 117(26):7174-84. PubMed ID: 21540460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCR-negative chronic myeloid leukemia in relapse after bone marrow transplantation is susceptible to remission induction by donor lymphocyte infusions.
    Lovey PY; Darbellay R; Cabrol C; Roux E; Starobinski M; Helg C; Kovacsovics T; Chapuis B
    Eur J Haematol; 1999 Oct; 63(4):280-1. PubMed ID: 10530422
    [No Abstract]   [Full Text] [Related]  

  • 17. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
    Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cellular immunotherapy in chronic myeloid leukemia].
    Fernández MN
    Sangre (Barc); 1998 Apr; 43(2):164-70. PubMed ID: 9656778
    [No Abstract]   [Full Text] [Related]  

  • 19. Monitoring of minimal residual disease after allografting: a requirement to guide DLI treatment?
    Dazzi F
    Ann Hematol; 2002; 81 Suppl 2():S29-30. PubMed ID: 12611066
    [No Abstract]   [Full Text] [Related]  

  • 20. Graft failure after donor leucocyte infusion in relapsed chronic myeloid leukaemia: successful treatment with cyclophosphamide and antithymocyte globulin followed by peripheral blood stem cell infusion.
    Keil F; Kalhs P; Haas OA; Fritsch G; Mitterbauer G; Brugger S; Lechner K; Schwarzinger I; Mannhalter C; Linkesch W; Kurz M; Greinix HT
    Br J Haematol; 1996 Jul; 94(1):120-2. PubMed ID: 8757519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.